Pfizer
Pipeline approvals against a post-pandemic revenue reset.
In coverage since May 2026
Prediction record
Our call accuracy 5 of 6 right
21 of 25 tracked companies Market accuracy on Pfizer 4 of 6 right
market baseline, same contracts Brier edge vs market −0.057 mean
12 of 25 in coverage, by edge Scored events
Q1 2026 Beats quarterly consensus we said 36% No
Q1 2026 Pfizer closes above a key technical level by month-end we said 46% No
May 2026 10%+ single-day move in the stock this quarter we said 19% No
Jun 2026 Pfizer announces a new buyback or capital-return plan we said 66% No
Jun 2026 Pfizer guidance raise on the next print we said 26% No
Jul 2026 A 10%+ single-day drop in the stock this quarter we said 27% No
In the record
"Pfizer never misses on pipeline approvals" (trader shorthand) False
"Pfizer is the safest name in its sector" (widely repeated) Mostly true